Imaging kidney metabolism in chronic kidney disease and polycystic kidney disease with MRI

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic kidney disease, adults with autosomal dominant polycystic kidney disease (ADPKD), and healthy volunteers. It uses a special MRI scan to look at how the kidneys work.

Age

18 to 85 years

Sex

All sexes can join. Women who have not yet reached menopause must have a negative pregnancy test on site.

Disease stage

One group has autosomal dominant polycystic kidney disease with eGFR above 60. Another group has chronic kidney disease for any reason except polycystic kidney disease. A third group is healthy volunteers.

Biomarker or test result

Chronic kidney disease patients need a recent kidney biopsy, done within 6 months of the MRI.

Main reasons for not taking part

• Cannot have an MRI for safety reasons (for example a pacemaker, metal in the body, unsafe implants or claustrophobia)
• Significant heart disease or significant lung disease or severe asthma
• Competing kidney or whole-body disease (some conditions such as well-regulated diabetes and high blood pressure are allowed)
• Renovascular disease
• Allergy to pyruvate

The registry criteria, word for word

What the trial wants to find out

In this study, we aim to assess the metabolic signature of CKD and PDK using multi-parametric MRI. The study will include healthy volunteers (N=8), CKD patients (N=12), PKD patients (N=10). PDK patients: a. The metabolic shift towards glycolysis compared with healthy kidneys can be detected using MRI with hyperpolarized pyruvate.